2012
A catalytically inactive mutant of the deubiquitylase YOD-1 enhances antigen cross-presentation
Sehrawat S, Koenig PA, Kirak O, Schlieker C, Fankhauser M, Ploegh HL. A catalytically inactive mutant of the deubiquitylase YOD-1 enhances antigen cross-presentation. Blood 2012, 121: 1145-1156. PMID: 23243279, PMCID: PMC3575758, DOI: 10.1182/blood-2012-08-447409.Peer-Reviewed Original ResearchMeSH KeywordsAdoptive TransferAnimalsAntigen-Presenting CellsATP Binding Cassette Transporter, Subfamily B, Member 2ATP-Binding Cassette TransportersBrefeldin ACD8-Positive T-LymphocytesCross-PrimingFemaleHydrogen-Ion ConcentrationImmunizationMaleMiceMice, Inbred C57BLMice, KnockoutMice, TransgenicMutation, MissenseOvalbuminPeptide FragmentsRhadinovirusUbiquitin ThiolesteraseConceptsAntigen presenting cellsT cellsPresent exogenous antigensRecombinant herpes virusT cell responsesExogenous antigensPresenting cellsSIINFEKL peptideRecombinant influenzaAntigen processingInclusion of inhibitorsEnhanced expansionMHV-68AntigenImmunizationInfectionVirusCellsCrosspresentationImproved controlInfluenzaMiceSIINFEKL
1991
L-Deprenyl (Selegiline) Added to Sinemet CR in the Management of Parkinson's Disease Patients With Motor Response Fluctuations.
Cedarbaum JM, Toy LH, Green-Parsons A. L-Deprenyl (Selegiline) Added to Sinemet CR in the Management of Parkinson's Disease Patients With Motor Response Fluctuations. Clinical Neuropharmacology 1991, 14: 228. PMID: 1906374, DOI: 10.1097/00002826-199106000-00005.Peer-Reviewed Original ResearchConceptsSinemet CRParkinson's diseaseResponse fluctuationsDisease patientsL-deprenylMean interdose intervalTherapeutic response fluctuationsAdvanced Parkinson's diseaseMotor response fluctuationsParkinson's disease patientsLevodopa intakeMotor fluctuationsInterdose intervalTreatment regimensPatientsSignificant reductionDeprenylDiseaseRegimensDyskinesiaImproved control
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply